Cathie's Ark Logo
Intellia Therapeutics Inc Logo

Combined Holdings of Intellia Therapeutics (NTLA) - Updated Daily

Gene TherapyGenomicsSynthetic BiologyGene Base EditingCRSPR Gene Editing
Date
Direction
Shares
Fund Weight
Fund
January 30, 2023
BUY1.773k0.0031%ARKG
January 30, 2023
BUY5.989k0.0031%ARKK
January 26, 2023
BUY46.739k0.081%ARKG
January 26, 2023
BUY147.825k0.0786%ARKK
January 23, 2023
BUY8.770k0.0044%ARKK

Key Statistics

⚖️Weighting🧢Market Cap
2.51%$3.26b
🏋️‍♀️Weight Rank Across All Funds🌏Country
14🇺🇸United States
💳ARK Estimated Cost Average🎫ARK Ownership Percent
$54.51 - ARKG$62.04 - ARKK
9.71%
Description
Intellia Therapeutics is a leading clinical-stage genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creating enhanced engineered cells that can treat oncological and immunological diseases. Intellia's combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create new classes of therapeutic products.
Website
www.intelliatx.com

Other ETFs That Hold NTLA

Ticker
NameWeight
ARKGARK Genomic Revolution ETF3.95%
ARKKARK Innovation ETF3.77%
GNOMGlobal X Genomics & Biotechnology ETF3.28%
XBISPDR® S&P Biotech ETF1.12%